Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Publication of BE717371ApublicationCriticalpatent/BE717371A/fr
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K49/00—Preparations for testing in vivo
A61K49/04—X-ray contrast preparations
A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
A61K49/0452—Solutions, e.g. for injection
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K49/00—Preparations for testing in vivo
A61K49/04—X-ray contrast preparations
A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
A61K49/0495—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound intended for oral administration
Landscapes
Health & Medical Sciences
(AREA)
Epidemiology
(AREA)
Life Sciences & Earth Sciences
(AREA)
Animal Behavior & Ethology
(AREA)
General Health & Medical Sciences
(AREA)
Public Health
(AREA)
Veterinary Medicine
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Cyclische azotierte Ligande, Metallkomplexe gebildet aus diesen Liganden, diagnostische Präparate, die diese Komplexe enthalten und Verfahren zur Herstellung dieser Ligande
Process for producing 1,3-bis-/3-(mono- or poly-hydroxy)acylamino-5-(mono-or polyhydroxyalkyl)-aminocarbonyl-2,4,6-triiodo-benzoyl-amino/-hydroxy- or hydroxyalkyl-propanes and x-ray contrast media containing them